Condition: Treatment Free Remission · Chronic Myeloid Leukemia · Sponsor: University of Turin, Italy
The investigator propose an extension of the previous National, multicentric study, promoting an observational registry, both retrospective and prospective, in order to expand and further characterize the series of Italian patients with Philadelphia-positive, chronic phase CML (CP-CML) who discontinue TKIs in an off-protocol setting. As safety concerns may arise for patients receiving long-term treatments, and due to the growing number of patients discontinuing TKIs in clinical practice, the study aim to collect all available data regarding feasibility and freedom from progression of the cohort of patients.
This description comes directly from the study's public registry record.
Carmen Fava, MD, PhD · 0115085523 · carmen.fava@unito.it
Giulia Piraccini, MA · 0115085523 · giulia.piraccini1@gmail.com
Always discuss trial participation with your own doctor first.
| Division of Hematology-AO Mauriziano Hospital, University of Turin | Turin, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04769947